Haemonetics Co. (NYSE:HAE) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue lessened its position in shares of Haemonetics Co. (NYSE:HAE) by 9.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,480 shares of the medical instruments supplier’s stock after selling 580 shares during the quarter. State of Alaska Department of Revenue’s holdings in Haemonetics were worth $468,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in HAE. Meeder Asset Management Inc. raised its position in Haemonetics by 65.2% during the fourth quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 135 shares during the last quarter. State of Wyoming purchased a new position in shares of Haemonetics during the 4th quarter worth approximately $28,000. Carmel Capital Partners LLC acquired a new position in shares of Haemonetics during the 3rd quarter worth approximately $30,000. Belpointe Asset Management LLC lifted its stake in Haemonetics by 65.5% in the 1st quarter. Belpointe Asset Management LLC now owns 455 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 180 shares in the last quarter. Finally, AdvisorNet Financial Inc grew its holdings in Haemonetics by 3,963.6% during the 3rd quarter. AdvisorNet Financial Inc now owns 447 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 436 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Trading Down 1.6 %

Shares of Haemonetics stock opened at $85.15 on Friday. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $95.26. The business’s fifty day moving average is $78.23 and its two-hundred day moving average is $82.91. The company has a quick ratio of 1.76, a current ratio of 2.92 and a debt-to-equity ratio of 0.91. The firm has a market cap of $4.32 billion, a PE ratio of 34.61, a P/E/G ratio of 2.03 and a beta of 0.36.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.10. The firm had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. During the same period last year, the company earned $0.85 EPS. Analysts anticipate that Haemonetics Co. will post 3.95 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HAE. StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TheStreet downgraded shares of Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $105.00 price target on shares of Haemonetics in a research note on Friday.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.